Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial

Inclusion Criteria: * Subject is \> 18 years of age. * Subject is able to undergo diagnostic angiography procedure and is found suitable to receive such a device at the femoral arterial puncture site in order to reduce time to hemostasis. * Subject or his/her legal guardian understands the nature of the procedure, and provides written informed consent prior to the procedure. * Subject is available and willing to participate in follow-up through 30 days post femoral closure. Exclusion Criteria: * Subject with known allergies to polylactic acid (PLA), polyglycolic acid (PGA) or polydioxanone (PDO) polymers * Subject with severe acute non-cardiac systemic disease * Subject with evidence of systemic infection * Subject where bacterial contamination of the procedural sheath or surrounding tissues may have occurred as this may increase risk of infection * Subject with coagulopathy (bleeding disorders, including thrombocytopenia, hemophilia, etc.) * Subject taking thrombolytic medication which reduces fibrinogen to less than 100 mg/dl * Subject who has had a previous arterial access in the femoral artery on the treatment side with an existing hematoma \>5 cm in diameter * Subject who is unable to ambulate at baseline * Subject who has had another closure device used in the treatment side within the previous 90 days * Subject who requires re-entry of the treatment side planned within the next 90 days post-procedure * Subject has a history of surgical repair on the treatment side *…